MX2020009326A - Anticuerpos anti-claudina 18.2 y usos de los mismos. - Google Patents

Anticuerpos anti-claudina 18.2 y usos de los mismos.

Info

Publication number
MX2020009326A
MX2020009326A MX2020009326A MX2020009326A MX2020009326A MX 2020009326 A MX2020009326 A MX 2020009326A MX 2020009326 A MX2020009326 A MX 2020009326A MX 2020009326 A MX2020009326 A MX 2020009326A MX 2020009326 A MX2020009326 A MX 2020009326A
Authority
MX
Mexico
Prior art keywords
antibodies
claudin
antigen
cancer
compositions
Prior art date
Application number
MX2020009326A
Other languages
English (en)
Inventor
Minghan Wang
Hui Zou
Haiqun Jia
Original Assignee
Phanes Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phanes Therapeutics Inc filed Critical Phanes Therapeutics Inc
Publication of MX2020009326A publication Critical patent/MX2020009326A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen anticuerpos anti-CLDN18.2 y fragmentos de unión al antígeno de los mismos; también se describen los ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, y métodos para producir los anticuerpos y usar los anticuerpos para tratar o prevenir las enfermedades tales como cáncer y/o una enfermedad inflamatoria.
MX2020009326A 2018-03-08 2019-03-06 Anticuerpos anti-claudina 18.2 y usos de los mismos. MX2020009326A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862640288P 2018-03-08 2018-03-08
US201862714254P 2018-08-03 2018-08-03
PCT/US2019/020872 WO2019173420A1 (en) 2018-03-08 2019-03-06 Anti-claudin 18.2 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2020009326A true MX2020009326A (es) 2020-10-08

Family

ID=67847436

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009326A MX2020009326A (es) 2018-03-08 2019-03-06 Anticuerpos anti-claudina 18.2 y usos de los mismos.

Country Status (13)

Country Link
US (1) US11555070B2 (es)
EP (1) EP3762031A4 (es)
JP (1) JP7398380B2 (es)
KR (1) KR20200129116A (es)
CN (1) CN111836644A (es)
AU (1) AU2019232762B2 (es)
BR (1) BR112020015479A2 (es)
CA (1) CA3089653A1 (es)
IL (1) IL276830A (es)
MX (1) MX2020009326A (es)
SG (1) SG11202007055QA (es)
WO (1) WO2019173420A1 (es)
ZA (1) ZA202004730B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108398YA (en) 2019-02-01 2021-08-30 Novarock Biotherapeutics Ltd Anti-claudin 18 antibodies and methods of use thereof
US20220184126A1 (en) * 2019-03-29 2022-06-16 Phanes Therapeutis, Inc. Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
WO2021003082A1 (en) * 2019-07-03 2021-01-07 Phanes Therapeutics, Inc. Anti-claudin 18.2/anti-cd47 bispecific antibodies and uses thereof
CN114981303B (zh) * 2019-09-13 2024-01-23 安徽俊义医疗管理咨询有限公司 人源化抗Claudin18.2（CLDN18.2）抗体
CN112707965A (zh) * 2019-09-30 2021-04-27 和铂医药(苏州)有限公司 靶向cldn18.2的抗体及其制备方法和应用
WO2021111003A1 (en) 2019-12-06 2021-06-10 SOTIO a.s. Humanized cldn18.2 antibodies
MX2022007849A (es) 2019-12-23 2022-07-19 Sotio Biotech A S Anticuerpos especificos contra la claudina 18.2 tumoral.
CA3166498A1 (en) * 2020-01-03 2021-07-08 Crage Medical Co., Limited Anti-claudin 18.2 antibody and use thereof
EP4090687A4 (en) * 2020-01-19 2024-02-21 Nanjing Genscript Biotech Co Ltd MULTI-SPECIFIC ANTI-CLAUDINE-18.2 CONSTRUCTS AND THEIR USES
WO2021160155A1 (zh) * 2020-02-10 2021-08-19 上海诗健生物科技有限公司 密蛋白18.2的抗体及其用途
WO2021160154A1 (zh) * 2020-02-10 2021-08-19 上海诗健生物科技有限公司 Cldn18.2抗体及其用途
US11970533B2 (en) 2020-06-18 2024-04-30 Sparx Bioscience Limited Bispecific antibodies targeting human claudin 18.2 and programmed death-ligand 1 (PD-L1)
WO2022063272A1 (en) * 2020-09-28 2022-03-31 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-claudin18 antibodies
CN112480248B (zh) * 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
EP4267194A1 (en) 2020-12-23 2023-11-01 SOTIO Biotech a.s. Tumor-specific claudin 18.2 antibody-drug conjugates
CN113321730B (zh) * 2021-01-11 2023-10-10 上海莱馥医疗科技有限公司 Cldn18.2抗体及其应用
CN114805571B (zh) * 2021-01-28 2023-08-25 广西鹭港生物医药科技有限公司 抗cldn18.2抗体及其应用
CN112940124B (zh) * 2021-04-14 2022-04-05 南京凯地医疗技术有限公司 靶向Claudin18.2的人源化单克隆抗体及其制备方法和应用
CN112979817B (zh) * 2021-04-27 2021-08-13 宝船生物医药科技(上海)有限公司 一种识别抗cldn18_2抗体的单克隆抗体及其制备方法和应用
CN117642425A (zh) * 2021-05-31 2024-03-01 石家庄以岭药业股份有限公司 针对CLDN18.2的单克隆抗体及其Fc工程化形式
CN116102649A (zh) * 2021-11-11 2023-05-12 上海生物制品研究所有限责任公司 抗cldn18.2单克隆抗体及其应用
WO2023240086A1 (en) * 2022-06-07 2023-12-14 Unm Rainforest Innovations Humanized non-opioid composition and therapies for pain management
CN117229398A (zh) * 2022-06-15 2023-12-15 中山康方生物医药有限公司 抗cldn18.2抗体、其药物组合物及用途
WO2024002257A1 (en) * 2022-06-30 2024-01-04 Suzhou Transcenta Therapeutics Co., Ltd. Stable pharmaceutical formulation comprising an anti-cldn18.2 antibody
CN117777288A (zh) * 2022-09-29 2024-03-29 南京博望医药科技有限公司 抗密蛋白18.2的抗体

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003285878B2 (en) * 2002-11-07 2011-04-28 Immunogen, Inc. Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
EP2462162B1 (en) * 2009-08-06 2016-10-12 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
CA2786940C (en) 2010-03-16 2019-09-24 Biontech Ag Tumor vaccination involving a humoral immune response, and proteins therefor including all or a portion of a hepatitis b virus core antigen protein and an epitope of claudin 18.2
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
EP3254695B1 (en) * 2012-05-23 2020-09-09 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174403A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN105073776B (zh) * 2012-11-13 2019-04-12 拜恩科技股份公司 用于治疗表达紧密连接蛋白的癌症疾病的制剂
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
EP4177273A1 (en) * 2013-02-20 2023-05-10 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3670537A1 (en) * 2013-03-18 2020-06-24 Astellas Pharma Inc. Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3099706B1 (en) 2014-01-29 2018-10-31 BioNTech AG Peptide mimotopes of claudin 18.2 and uses thereof
AU2015266958A1 (en) * 2014-05-28 2016-12-08 Agenus Inc. Anti-GITR antibodies and methods of use thereof
EP3166970B1 (en) * 2014-07-10 2021-03-10 BioArctic AB Improved a-beta protofibril binding antibodies
MA40871A (fr) * 2014-10-29 2017-09-05 Novartis Ag Expression directe d'anticorps
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016165765A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
WO2016180468A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
WO2016180467A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
SG11201808911SA (en) * 2016-04-13 2018-11-29 Sanofi Sa Trispecific and/or trivalent binding proteins
SG11201900171QA (en) 2016-07-08 2019-02-27 Carsgen Therapeutics Co Ltd Antibody for anti-claudin 18a2 and use thereof

Also Published As

Publication number Publication date
JP7398380B2 (ja) 2023-12-14
BR112020015479A2 (pt) 2020-12-08
CA3089653A1 (en) 2019-09-12
EP3762031A1 (en) 2021-01-13
AU2019232762A1 (en) 2020-08-27
US20200399364A1 (en) 2020-12-24
JP2021514664A (ja) 2021-06-17
EP3762031A4 (en) 2021-12-22
ZA202004730B (en) 2024-01-31
IL276830A (en) 2020-10-29
KR20200129116A (ko) 2020-11-17
US11555070B2 (en) 2023-01-17
CN111836644A (zh) 2020-10-27
WO2019173420A1 (en) 2019-09-12
SG11202007055QA (en) 2020-09-29
AU2019232762B2 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
ZA202000373B (en) Anti-cd47 antibodies and uses thereof
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
MX2020011914A (es) Anticuerpos anti-dll3 y usos de los mismos.
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
MY194997A (en) Anti-ccr7 antibody drug conjugates
MX2021004454A (es) Anticuerpos anti-sinucleina.
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
MX2022015248A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
CR20220505A (es) Anticuerpos anti-phf-tau y usos de estos
MX2021012769A (es) Anticuerpos bloqueadores cd73.
WO2020123330A3 (en) Anti-alpha-synuclein antibodies and uses thereof
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
EA202092122A1 (ru) Антитела против tip-1 и их применения
MX2022013920A (es) Anticuerpos anti-antigeno asociado con tumor y usos de los mismos.
AU2018345715A8 (en) DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer
ZA202110285B (en) Antibodies and methods of use
MX2021013532A (es) Materiales y metodos para modular la inmunidad mediada por celulas t.
EA202092123A1 (ru) Антитела против клаудина 18.2 и их применения
MX2020013243A (es) Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos.
EA202092121A1 (ru) Антитела против cd73 и их применения